Weight loss of 15.3% sets a new record! Eli Lilly (LLY.US) Riluzole leads the next generation of weight loss drugs.

Eli Lilly & Company (LLY.US) experimental drug Retatrutide has attracted attention because it has achieved weight loss effects surpassing all current market drugs in diabetic patients, highlighting the potential of this drug in the increasingly crowded next generation therapy competition. Lilly said in a statement on Thursday that patients using the highest dose of Retatrutide experienced an average weight loss of 15.3% in a statistical analysis that included those who discontinued the drug. This late-stage trial result easily surpassed the earlier trial data of Lilly's major diabetes drug Mounjaro. Lilly stated that this once-weekly injected drug reduced blood sugar by 1.9% in approximately nine months, roughly equivalent to that of Mounjaro, which was approved in 2022. Retatrutide is a cornerstone product in Lilly's obesity business layout, with analysts predicting sales to exceed $10.6 billion by 2036. Lilly sees it as a choice for more severe obesity patients, who may require stronger treatment options than the company's Zepbound or Novo Nordisk A/S Sponsored ADR Class BWegovy. Favorable trial results may give Lilly a greater advantage in the competition for new diabetes and weight loss drugs on the market. The company is conducting research on Retatrutide for diabetes, obesity, and other related indications. The latest trial aims to measure its effectiveness in controlling blood sugar (measured by A1C levels) and compare it with a placebo in diabetic patients. The trial also evaluates the weight loss effects, which are often more challenging for diabetic patients. Kenneth Caste, Head of Lilly's Cardiometabolic Business, said in a statement, "These results demonstrate the enormous potential of this novel molecule for type 2 diabetes patients." Lilly stated that more detailed results will be presented at an upcoming medical conference. These new data in the field of diabetes provide more evidence for Lilly to eventually submit for regulatory approval. Last December, the company reported the results of another study showing that obese patients lost nearly a quarter of their weight, exceeding market expectations, with some patients dropping out of the trial due to excessive weight loss. In the coming months, Lilly plans to release more research results. Retatrutide acts by simulating the actions of three different intestinal hormones - GLP-1, GIP, and glucagon-like peptide-1, giving it an advantage over drugs with fewer targets such as Mounjaro. Lilly has excelled in the development of these complex molecules, which have been shown to produce more significant weight loss effects. The most common adverse reactions in the trial were nausea, vomiting, and diarrhea, similar to other drugs in the same class. A few patients also experienced sensory disturbances, manifested as sensations of burning, tingling, or intense itching. Lilly stated that approximately 5% of patients using the highest dose of the drug discontinued treatment due to side effects.